See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Liberation Day
Social Media
Trade War
Stock Markets
Donald Trump
Natural Disasters
Recession
Artificial Intelligence
US Economy
Trade
European Union
Published • loading... • Updated

Oncotelic completes Phase 1 study of OT-101 and IL-2 in metastatic solid tumors - BioTuesdays

Summary by biotuesdays.com
Oncotelic Therapeutics (OTCQB:OTLC) announced it has completed Phase 1 of its trial evaluating OT-101 in combination with IL-2 for advanced metastatic tumors. According to Oncotelic, this announcement coincides with a presentation delivered by Vuong Trieu, Ph.D., chairman and CEO of Oncotelic, at the 2025 Symposium on World Cancer Research, describing the central role of TGFβ2 in immune suppression across multiple diseases. The presentation also…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
biotuesdays.combiotuesdays.com

Oncotelic completes Phase 1 study of OT-101 and IL-2 in metastatic solid tumors - BioTuesdays

Oncotelic Therapeutics (OTCQB:OTLC) announced it has completed Phase 1 of its trial evaluating OT-101 in combination with IL-2 for advanced metastatic tumors. According to Oncotelic, this announcement coincides with a presentation delivered by Vuong Trieu, Ph.D., chairman and CEO of Oncotelic, at the 2025 Symposium on World Cancer Research, describing the central role of TGFβ2 in immune suppression across multiple diseases. The presentation also…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

biotuesdays.com broke the news in on Tuesday, March 25, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal